ArticleBMC cardiovascular disorders2025
Prognostic value of hemoglobin to serum creatinine ratio in ST-elevation myocardial infarction: a secondary analysis based on a cohort study.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic value of hemoglobin-to-serum creatinine ratio in patients with coronary artery disease and reduced kidney function following percutaneous coronary intervention.Frontiers in cardiovascular medicine · 2026Article
- Dual-pathway model of IL-6 and HSP22/HSP27 dynamics predicts post-PCI MACE in STEMI patients.BMC cardiovascular disorders · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe long-term relationship between hemoglobin to serum creatinine (HB/SCr) ratio and clinical outcomes in ST-elevation myocardial infarction (STEMI) remains uncertain. This study aimed to determine the predictive value of the HB/SCr ratio for long-term major adverse cardiovascular events (MACE) in patients with STEMI.
methodsThis study was based on a prospective cohort conducted in China, which included 460 STEMI patients who successfully underwent primary percutaneous coronary intervention. Cox proportional hazards models were utilized to explore the relationship between the HB/SCr ratio and MACE in STEMI patients over a 30-month follow-up period. The predictive value of the HB/SCr ratio for MACE was assessed using the receiver operating characteristic curve.
resultsA total of 118 patients (26%) developed MACE during the follow-up period. After adjusting for confounding factors, a lower HB/SCr ratio emerged as a significant predictor of MACE in STEMI patients. Subgroup analyses indicated that the HB/SCr ratio was inversely associated with MACE in patients aged ≥ 60 years, males, those with a history of hypertension, individuals experiencing anterior wall myocardial infarction, patients classified as Killip grade I, and those receiving single stent implantation. Sensitivity analysis revealed that the inverse association between the HB/SCr ratio and MACE occurrence persisted in patients with normal hemoglobin levels. The area under the curve for the HB/SCr ratio in predicting MACE was 0.611.
conclusionsThe baseline HB/SCr ratio was inversely associated with MACE, suggesting that it may serve as a useful biomarker for identifying high-risk STEMI patients at an early stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.